Professor Nir Peled Joins SciSparc’s Advisory Board
![Professor Nir Peled Joins SciSparc’s Advisory Board](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Professor Nir Peled Joins SciSparc's Advisory Board
Professor Nir Peled, a highly regarded oncologist, has been appointed to the Scientific Advisory Board of MitoCareX Bio Ltd., a collaborative venture between SciSparc Ltd. (NASDAQ: SPRC) and Dr. Alon Silberman. This appointment reflects SciSparc's ongoing commitment to advancing innovative cancer treatments and its mission to develop therapies for central nervous system disorders.
About Professor Nir Peled
Professor Nir Peled currently serves as the Director of the Oncology Department at Shaare Zedek Medical Center in Jerusalem. He is board certified in internal medicine, pulmonology, and medical oncology, and is recognized as a leading expert in thoracic oncology. His work in lung cancer research and treatment has earned him international acclaim.
Accomplishments in Oncology
Professor Peled has held prestigious roles, including board membership in the International Association for the Study of Lung Cancer (IASLC) and Chair of the Global Multidisciplinary Practice Standards Committee. He recently completed his term as Chair of the Thoracic Cancer Assembly of the European Thoracic Society. His research has primarily focused on personalized targeted therapy, immunotherapy, cancer evolution, and biomarker development, contributing significantly to early lung cancer detection. He has published over 250 peer-reviewed papers in these areas.
Innovation and Research at MitoCareX
Dr. Alon Silberman, CEO of MitoCareX, welcomed Professor Peled's expertise, emphasizing the importance of his contributions to the company's cancer treatment technologies. MitoCareX focuses on drug discovery and development for life-threatening conditions, particularly through research on the mitochondrial SLC25 protein family.
Advances in Lung Cancer Research
One of the significant milestones for MitoCareX has been validating the involvement of the SLC25 carrier protein in Non-Small Cell Lung Cancer (NSCLC). This breakthrough was achieved using advanced genetic manipulation techniques and 3D spheroid systems that replicate human tumors.
The company utilizes a sophisticated computational platform, including its proprietary MITOLINE™ algorithm, to screen millions of small molecules, leading to the discovery of multiple potential anti-cancer treatments. This work has significantly expanded MitoCareX's therapeutic pipeline.
About SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company dedicated to developing cannabinoid-based therapies. Its key programs include SCI-110 for Tourette Syndrome and agitation in Alzheimer’s disease, SCI-160 for pain management, and SCI-210 for treating ASD and status epilepticus. SciSparc's experienced team is committed to advancing cannabinoid pharmaceutical technologies.
Strategic Growth and Future Plans
SciSparc is continuously enhancing its drug development portfolio while exploring the therapeutic potential of cannabinoid medications. The company also holds a controlling interest in a subsidiary focused on hemp seed oil products sold on Amazon Marketplace, positioning itself for strategic growth in diverse health markets.
Frequently Asked Questions
Who is Professor Nir Peled?
Professor Nir Peled is a renowned oncologist appointed to the Scientific Advisory Board of MitoCareX, contributing his expertise in thoracic oncology.
What is MitoCareX?
MitoCareX is a venture of SciSparc focusing on drug discovery and development targeting mitochondrial SLC25 proteins for cancer therapies.
What role will Professor Peled play at MitoCareX?
He will provide valuable insights and guidance in advancing the company's innovative cancer treatment technologies.
What are SciSparc's main drug development focus areas?
SciSparc's current focus includes cannabinoid-based treatments for disorders such as Tourette Syndrome, Alzheimer's, pain management, and autism spectrum disorder.
How is MitoCareX advancing cancer therapy?
MitoCareX utilizes advanced computational drug discovery methods and validation studies to identify promising small molecules for cancer treatment.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Dr. Brittany Mitchell Joins Washington Gastroenterology Team
- Svitzer Group Notifies Board Transactions in Share Market
- Management Board Update at A/S Delfi
- AvidXchange Board Approves $100 Million Share Repurchase Plan
- Steve Gray to Retire from Range Resources Board
- Abercrombie & Fitch Appoints Andrew Clarke to Board
- First Watch Enhances Board with New Appointments
- Innovative Homebuilding Techniques by LSU Professor Lin
- ClearCloser Elevates Board with Industry Leader Christopher Campbell
- Dr. Elissa Lin Joins Gastroenterology Consultants